OCU410-101 (Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental gene transfer drug called OCU410 (the study drug) is a safe and effective option for geographic atrophy secondary to dry age-related macular degeneration.

What is the Condition Being Studied?

Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Who Can Participate in the Study?

Adults ages 50+ who:

- Are diagnosed with geographic atrophy

- Have never received a gene therapy or cell therapy product to treat vision problems

- Do not smoke

For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.

Age Group

What is Involved?

If you choose to join the study, you will receive:

- Either a low dose, or a medium dose, or a high dose of the study drug; OR

- You will receive a placebo (inactive substance with no drug in it) and be in the control group

You will be in touch with the study team for about 15 months and you will visit our clinic at the Duke Eye Center up to 8 times. At various visits, you will have blood tests, eye exams, and vision tests.

Study Details

Full Title
A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. OCU410-101
Principal Investigator
Protocol Number
IRB: PRO00114282
NCT: NCT06018558
Phase I/II
Enrollment Status
Open for Enrollment